
An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.
The FDA has approved Taclonex, a combination topical consisting of calcipotriene 0.005% and betamethasone dipropionate 0.064%, for the treatment of psoriasis vulgaris in adults. Warner Chilcott plans to launch the new ointment in the first half of 2006.






